{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:49:26Z","timestamp":1790790566712,"version":"4.1.0"},"reference-count":38,"publisher":"BMJ","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Archives of Disease in Childhood"],"published-print":{"date-parts":[[1990,7,1]]},"DOI":"10.1136\/adc.65.7.732","type":"journal-article","created":{"date-parts":[[2008,12,22]],"date-time":"2008-12-22T22:39:16Z","timestamp":1229985556000},"page":"732-738","source":"Crossref","is-referenced-by-count":92,"title":["Nephrotoxicity after ifosfamide."],"prefix":"10.1136","volume":"65","author":[{"given":"R","family":"Skinner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A D","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M G","family":"Coulthard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A W","family":"Craft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","reference":[{"key":"ref_1","first-page":"258","article-title":"A phase II study of ifosfamide in children with recurrent solid tumours","volume":"15","author":"Pinkerton, C.R.; Rogers, H.; James, C.","year":"1985","unstructured":"Pinkerton CR, Rogers H, James C, et al. A phase II study of ifosfamide in children with recurrent solid tumours. Cancer Chemother Pharmacol 1985;15:258-62.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref_2","first-page":"2","article-title":"A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people","volume":"18","author":"Magrath, I.; Sandlund, J.; Raynor, A.; Rosenberg, S.; Arasi, V.; Miser, J.","year":"1986","unstructured":"Magrath I, Sandlund J, Raynor A, Rosenberg S, Arasi V, Miser J. A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother Pharmacol 1986;18(suppl 2):S25-8.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.1987.5.8.1191","article-title":"Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults","volume":"5","author":"Miser, J.S.; Kinseila, T.J.; Triche, T.J.","year":"1987","unstructured":"Miser JS, Kinseila TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:1191-8.","journal-title":"J Clin Oncol"},{"key":"ref_4","first-page":"131","article-title":"Phase II trial of ifosfamide in children with malignant solid tumors","volume":"71","author":"Pratt, C.B.; Horowitz, M.E.; Meyer, W.H.","year":"1987","unstructured":"Pratt CB, Horowitz ME, Meyer WH, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 1987;71:131-5.","journal-title":"Cancer Treat Rep"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/clinchem\/26.9.1251","article-title":"An optimised assay of alanine aminopeptidase activity in urine","volume":"26","author":"Jung, K.; Scholz, D.","year":"1980","unstructured":"Jung K, Scholz D. An optimised assay of alanine aminopeptidase activity in urine. Clin Chem 1980;26:1251-4.","journal-title":"Clin Chem"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF00273416","article-title":"Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin","volume":"22","author":"Skillen, A.W.; Buamah, P.K.; Cantwell, B.M.J.; Cornell, C.; Hodson, A.W.; Harris, A.L.","year":"1988","unstructured":"Skillen AW, Buamah PK, Cantwell BMJ, Cornell C, Hodson AW, Harris AL. Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9). Cancer Chemother Pharmacol 1988;22:228-34.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref_7","first-page":"551","article-title":"Renal handling of calcium, phosphate, and magnesium","author":"Sutton, R.A.L.; Dirks, J.H.","year":"1981","unstructured":"Sutton RAL, Dirks JH. Renal handling of calcium, phosphate, and magnesium. In: Brenner BM, Rector FC, eds. The kidney. Philadelphia: W B Saunders, 1981:551-618."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00862587","article-title":"Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet","volume":"2","author":"Brodehl, J.; Krause, A.; Hoyer, P.F.","year":"1988","unstructured":"Brodehl J, Krause A, Hoyer PF. Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet. Pediatric Nephrology 1988;2:183-9.","journal-title":"Pediatric Nephrology"},{"key":"ref_9","article-title":"Albumin and 02-microglobulin excretion in normal and diabetic children","author":"Fielding, B.A.","year":"1984","unstructured":"Fielding BA. Albumin and 02-microglobulin excretion in normal and diabetic children. Manchester: Manchester Polytechnic, 1984. (M Phil thesis.)"},{"key":"ref_10","first-page":"163","article-title":"Postnatal development of tubular phosphate reabsorption","volume":"17","author":"Brodehl, J.; Gellisen, K.; Weber, H.P.","year":"1982","unstructured":"Brodehl J, Gellisen K, Weber HP. Postnatal development of tubular phosphate reabsorption. Clin Nephrol 1982;17: 163-71.","journal-title":"Clin Nephrol"},{"key":"ref_11","first-page":"921","article-title":"Unexpected toxicity in patients treated with iphosphamide","volume":"32","author":"van Dyk JJ; HC, Falkson; van der Merwe AM; G, Falkson","year":"1972","unstructured":"van Dyk JJ, Falkson HC, van der Merwe AM, Falkson G. Unexpected toxicity in patients treated with iphosphamide. Cancer Res 1972;32:921-4.","journal-title":"Cancer Res"},{"key":"ref_12","first-page":"1103","article-title":"Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation","volume":"64","author":"Fossa, S.D.; Talle, K.","year":"1980","unstructured":"Fossa SD, Talle K. Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation. Cancer Treat Rep 1980;64:1103-8.","journal-title":"Cancer Treat Rep"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/1097-0142(19890215)63:4<649::AID-CNCR2820630408>3.0.CO;2-Z","article-title":"Ifosfamide-induced renal tubular defects","volume":"63","author":"Patterson, W.P.; Khoiasteh, A.","year":"1989","unstructured":"Patterson WP, Khoiasteh A. Ifosfamide-induced renal tubular defects. Cancer 1989;63:649-5 1.","journal-title":"Cancer"},{"key":"ref_14","first-page":"375","article-title":"Renal dysfunction after treatment with isophosphamide (NSC-109724)","volume":"58","author":"DeFronzo, R.A.; Abeloff, M.; Braine, H.; Humphrey, R.L.; Davis, P.J.","year":"1974","unstructured":"DeFronzo RA, Abeloff M, Braine H, Humphrey RL, Davis PJ. Renal dysfunction after treatment with isophosphamide (NSC-109724). Cancer Chemotherapy Reports 1974;58: 375-82.","journal-title":"Cancer Chemotherapy Reports"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0277-5379(84)90093-2","article-title":"Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity","volume":"20","author":"Sangster, G.; Kaye, S.B.; Calman, K.C.; Dalton, J.F.","year":"1984","unstructured":"Sangster G, Kaye SB, Calman KC, Dalton JF. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity. EurJ Cancer Clin Oncol 1984;20:435-6.","journal-title":"EurJ Cancer Clin Oncol"},{"key":"ref_16","first-page":"115","article-title":"High-dose ifosfamide in advanced osteosarcoma","volume":"69","author":"Marti, C.; Kroner, T.; Remagen, W.; Berchtold, W.; Cserhati, M.; Varini, M.","year":"1985","unstructured":"Marti C, Kroner T, Remagen W, Berchtold W, Cserhati M, Varini M. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 1985;69:115-7.","journal-title":"Cancer Treat Rep"},{"key":"ref_17","first-page":"499","article-title":"Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma","volume":"69","author":"Antman, K.H.; Montella, D.; Rosenbaum, C.; Schwen, M.","year":"1985","unstructured":"Antman KH, Montella D, Rosenbaum C, Schwen M. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 1985;69:499-504.","journal-title":"Cancer Treat Rep"},{"issue":"2","key":"ref_18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF00647445","article-title":"The role of ifosfamide in paediatric soft tissue sarcomas","volume":"18","author":"de Kraker J; PA, Voute","year":"1986","unstructured":"de Kraker J, Voute PA. The role of ifosfamide in paediatric soft tissue sarcomas. Cancer Chemother Pharmacol 1986;18 (suppl 2):S23-4.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref_19","first-page":"127","article-title":"Ifosfamideinduced subclinical tubular nephrotoxicity despite mesna","volume":"71","author":"Goren, M.P.; Wright, R.K.; Horowitz, M.E.; Pratt, C.B.","year":"1987","unstructured":"Goren MP, Wright RK, Horowitz ME, Pratt CB. Ifosfamideinduced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep 1987;71:127-30.","journal-title":"Cancer Treat Rep"},{"key":"ref_20","first-page":"121","article-title":"Fanconi syndrome after ifosfamide","volume":"23","author":"Moncrieff, M.; Foot, A.","year":"1989","unstructured":"Moncrieff M, Foot A. Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol 1989;23:121-2.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/BF00445929","article-title":"Nephrotoxicity associated with ifosfamide","volume":"148","author":"Smeitink, J.; Verreussel, M.; Schroder, C.; Lippens, R.","year":"1988","unstructured":"Smeitink J, Verreussel M, Schroder C, Lippens R. Nephrotoxicity associated with ifosfamide. EurJ Pediatr 1988;148: 164-6.","journal-title":"EurJ Pediatr"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0140-6736(89)92719-0","article-title":"Ifosfamideinduced Fanconi syndrome","volume":"i:","author":"Newbury-Ecob, R.A.; Noble, V.W.; Barbor, P.R.H.","year":"1989","unstructured":"Newbury-Ecob RA, Noble VW, Barbor PRH. Ifosfamideinduced Fanconi syndrome. Lancet 1989;i:1328.","journal-title":"Lancet"},{"key":"ref_23","article-title":"Acute ifosfamide-induced tubular toxicity","author":"Heney, D.; Lewis, I.J.; Bailey, C.C.","year":"1989","unstructured":"Heney D, Lewis IJ, Bailey CC. Acute ifosfamide-induced tubular toxicity. Lancet 1989;ii: 1034.","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/bmj.298.6687.1560","article-title":"Hypophosphataemic rickets after ifosfamide treatment in children","volume":"298","author":"Skinner, R.; Pearson, A.D.J.; Price, L.; Cunningham, K.; Craft, A.W.","year":"1989","unstructured":"Skinner R, Pearson ADJ, Price L, Cunningham K, Craft AW. Hypophosphataemic rickets after ifosfamide treatment in children. Br Med J 1989;298:1560-1.","journal-title":"Br Med J"},{"key":"ref_25","first-page":"8","article-title":"Toxicity of high dose ifosfamide in children","volume":"24","author":"Davies, S.M.; Pearson, A.D.J.; Craft, A.W.","year":"1989","unstructured":"Davies SM, Pearson ADJ, Craft AW. Toxicity of high dose ifosfamide in children. Cancer Chemother Pharmacol 1989; 24(suppl):S8-10.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/07357908609017511","article-title":"Present status of serum tumor markers in diagnosis, prognosis, and evaluation of therapy","volume":"4","author":"Cohn, S.L.; Lincoln, S.T.; Rosen, S.T.","year":"1986","unstructured":"Cohn SL, Lincoln ST, Rosen ST. Present status of serum tumor markers in diagnosis, prognosis, and evaluation of therapy. Cancer Invest 1986;4:305-27.","journal-title":"Cancer Invest"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/000456328201900422","article-title":"Assessment of renal tubular function and damage and their clinical significance","volume":"19","author":"Morgan, D.B.","year":"1982","unstructured":"Morgan DB. Assessment of renal tubular function and damage and their clinical significance. Ann Clin Biochem 1982;19:307-13.","journal-title":"Ann Clin Biochem"},{"key":"ref_28","first-page":"413","article-title":"Antibiotic nephrotoxicity","author":"Fillastre, J.P.; Kleinknecht, D.; Godin, M.; Viotte, G.; Olier, B.; Morin, J.P.","year":"1982","unstructured":"Fillastre JP, Kleinknecht D, Godin M, Viotte G, Olier B, Morin JP. Antibiotic nephrotoxicity. In: Bach PH, Bonner FW, Bridges JW, Lock EA, eds. Nephrotoxicity: assessment and pathogenesis. Chichester: John Wiley, 1982:413-21."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1001\/archinte.1988.00380110049010","article-title":"Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation","volume":"148","author":"Branch, R.A.","year":"1988","unstructured":"Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988;148:2389-94.","journal-title":"Arch Intern Med"},{"key":"ref_30","first-page":"1067","article-title":"Acyclovirinduced renal failure. Clinical course and histology","volume":"84","author":"Sawyer, M.H.; Webb, D.E.; Balow, J.E.; Straus, S.E.","year":"1988","unstructured":"Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovirinduced renal failure. Clinical course and histology. Am J Med 1988;84:1067-71.","journal-title":"Am J Med"},{"key":"ref_31","first-page":"175","article-title":"Nephrotoxicity of antitumoral agents","volume":"17","author":"Fillastre, J.P.; Viotte, G.; Morin, J.P.; Moulin, B.","year":"1988","unstructured":"Fillastre JP, Viotte G, Morin JP, Moulin B. Nephrotoxicity of antitumoral agents. Adv Nephrol 1988;17:175-218.","journal-title":"Adv Nephrol"},{"key":"ref_32","first-page":"85","article-title":"Hypomagnesaemia following treatment of childhood cancer with cisplatinum","volume":"I):","author":"Sheldon, W.; Welch, R.J.; Bonham, JR, Pearson; ADJ, Craft; A.W.","year":"1987","unstructured":"Sheldon W, Welch RJ, Bonham JR, Pearson ADJ, Craft AW. Hypomagnesaemia following treatment of childhood cancer with cisplatinum. Ann Clin Biochem 1987;24(suppl I):85-6.","journal-title":"Ann Clin Biochem"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/adc.53.9.740","article-title":"Case of tumour rickets","volume":"53","author":"Moncrieff, M.W.; Brenton, D.P.; Arthur, L.J.H.","year":"1978","unstructured":"Moncrieff MW, Brenton DP, Arthur LJH. Case of tumour rickets. Arch Dis Child 1978;53:740-5.","journal-title":"Arch Dis Child"},{"key":"ref_34","first-page":"17","article-title":"Nephrotoxicity of cis-diamminedichloroplatinum with or without ifosfamide in cancer treatment","volume":"1","author":"Hacke, M.; Schmoll, H.J.; Alt, J.M.; Baumann, K.; Stolte, H.","year":"1983","unstructured":"Hacke M, Schmoll HJ, Alt JM, Baumann K, Stolte H. Nephrotoxicity of cis-diamminedichloroplatinum with or without ifosfamide in cancer treatment. Clin Physiol Biochem 1983;1:17-26.","journal-title":"Clin Physiol Biochem"},{"key":"ref_35","first-page":"1457","article-title":"Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy","volume":"47","author":"Goren, M.P.; Wright, R.K.; Pratt, C.B.","year":"1987","unstructured":"Goren MP, Wright RK, Pratt CB, et al. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res 1987;47:1457-60.","journal-title":"Cancer Res"},{"key":"ref_36","first-page":"192","article-title":"Renal metabolism and clearance of 2-mercaptoethane sulphonate sodium (Mesna) and ifosfamide nephrotoxicity in children with solid tumors. IProceedings of","volume":"28","author":"Goren, M.P.; Wright, R.K.; Viar, M.J.; Pratt, C.B.","year":"1987","unstructured":"Goren MP, Wright RK, Viar MJ, Pratt CB. Renal metabolism and clearance of 2-mercaptoethane sulphonate sodium (Mesna) and ifosfamide nephrotoxicity in children with solid tumors. IProceedings of the Annual Meeting of the American Association for Cancer Research 1987;28:192.","journal-title":"the Annual Meeting of the American Association for Cancer Research"},{"key":"ref_37","first-page":"1451","article-title":"Sodium-2-mercaptoethane-sulfonate (mesna) and ifosfamide nephrotoxicity. Eur3J Cancer Clin Oncol","volume":"20","author":"Hilgard, P.; Burkert, H.","year":"1984","unstructured":"Hilgard P, Burkert H. Sodium-2-mercaptoethane-sulfonate (mesna) and ifosfamide nephrotoxicity. Eur3J Cancer Clin Oncol 1984;20:1451-2."},{"key":"ref_38","first-page":"5167","article-title":"Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients","volume":"48","author":"Hadidi, A.H.F.A.; Coulter, C.E.A.; Idle, JR","year":"1988","unstructured":"Hadidi AHFA, Coulter CEA, Idle JR. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients. Cancer Res 1988;48:5167-71.","journal-title":"Cancer Res"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/adc.65.7.732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T21:32:42Z","timestamp":1601069562000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/adc.65.7.732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,7,1]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1990,7,1]]}},"URL":"https:\/\/doi.org\/10.1136\/adc.65.7.732","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,7,1]]}}}